Revelation Biosciences annual stock-based compensation
2021
2022
2023
2024
2025
Revelation Biosciences Stock-Based Compensation Growth & History (REVB)
Revelation Biosciences's stock-based compensation was $595,368 for fiscal 2025.
View full Revelation Biosciences company overviewRevelation Biosciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $595,368 | $426,518 | +252.60% |
| 2024 | 2024-12-31 | $168,850 | $13,129 | +8.43% |
| 2023 | 2023-12-31 | $155,721 | −$145,395 | −48.29% |
| 2022 | 2022-12-31 | $301,116 | −$169,762 | −36.05% |
| 2021 | 2021-12-31 | $470,878 | — | — |
Revelation Biosciences quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $401,417 | $400,544 | +45881.33% |
| Q1 2026 | 2026-03-31 | $470,997 | $247,542 | +110.78% |
| Q4 2025 | 2025-12-31 | $370,166 | $297,600 | +410.11% |
| Q3 2025 | 2025-09-30 | $874 | −$31,221 | −97.28% |
| Q2 2025 | 2025-06-30 | $873 | −$31,222 | −97.28% |
| Q1 2025 | 2025-03-31 | $223,455 | $191,361 | +596.25% |
| Q4 2024 | 2024-12-31 | $72,566 | $40,471 | +126.10% |
| Q3 2024 | 2024-09-30 | $32,095 | −$1 | −0.00% |
| Q2 2024 | 2024-06-30 | $32,095 | −$27,340 | −46.00% |
| Q1 2024 | 2024-03-31 | $32,094 | −$1 | −0.00% |
| Q4 2023 | 2023-12-31 | $32,095 | −$266 | −0.82% |
| Q3 2023 | 2023-09-30 | $32,096 | −$8,579 | −21.09% |
| Q2 2023 | 2023-06-30 | $59,435 | −$30,753 | −34.10% |
| Q1 2023 | 2023-03-31 | $32,095 | −$105,797 | −76.72% |
| Q4 2022 | 2022-12-31 | $32,361 | −$73,551 | −69.45% |
| Q3 2022 | 2022-09-30 | $40,675 | −$90,645 | −69.03% |
| Q2 2022 | 2022-06-30 | $90,188 | −$41,133 | −31.32% |
| Q1 2022 | 2022-03-31 | $137,892 | $35,567 | +34.76% |
| Q4 2021 | 2021-12-31 | $105,912 | — | — |
| Q3 2021 | 2021-09-30 | $131,320 | — | — |
| Q2 2021 | 2021-06-30 | $131,321 | — | — |
| Q1 2021 | 2021-03-31 | $102,325 | — | — |
Revelation Biosciences stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Revelation Biosciences's stock-based compensation increased from $470,878 to $595,368, a change of $124,490. The latest reported quarter, Q2 2026, shows $401,417.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Revelation Biosciences source filings ↗